Did You Miss Biotech’s Rally? Innovation, AI and M&A Driving Stocks

Bullish Gator

Fidelity portfolio manager explains biotech’s outperformance, GLP‑1 progress, AI‑driven drug development, M&A trends, valuations and risks — what investors should know next.

Editorial companion

What stands out

Fidelity Investments' Market Sense episode Did You Miss Out On Biotech? highlights a quiet, year-long rotation into biotech driven by GLP-1 obesity drugs, cancer breakthroughs, AI-assisted discovery, and a flurry of dealmaking. For investors it’s a timely reminder that powerful pockets of the market can run while the rest of the market looks elsewhere; at the same time, the episode underscores a classic trade-off between chasing hot sectors and watching fundamentals in lagging names like payment processor and fintech firms.